You searched for: kombinationsterapi (Danska - Engelska)

kombinationsterapi
combination therapy

om kombinationsterapi
as combination therapy

pegasys kombinationsterapi
pegasys combination therapy

kombinationsterapi (cervixcancer):
combination therapy (cervical carcinoma)

kombinationsterapi med ribavirin:
combination therapy with ribavirin:

adjuverende kombinationsterapi ved kolonkræft
combination therapy in adjuvant colon cancer

kombinationsterapi med interferon alfa-2b
in combination with interferon alfa-2b

specielle populationer - mabthera kombinationsterapi
patient subpopulations - mabthera combination therapy

specielle populationer  mabthera kombinationsterapi
patient subpopulations - mabthera combination therapy

kombinationsterapi i 1. linjebehandling af metastatisk kolorektalkræft
combination therapy in first-line treatment of metastatic colorectal cancer

kombinationsterapi bør startes så tidligt som muligt og
combined therapy should be started as early as possible after symptoms start and continued for at least four weeks.

kombinationsterapi ved anvendelse af mann- whitney u test ke
ris combination therapy using the mann-whitney u test. b. p-value is from the pairwise comparison of trudexa monotherapy and trudexa/ methotrexate

brugen af kombinationsterapi bør overvejes i hvert enkelt tilfælde.
the use of combination therapy should be considered on a case-by-case basis.

dosis der skal administeres ved kombinationsterapi med interferon alfa-2b:
dose to be administered for the combination therapy with interferon alfa-2b:

azopt er primært vurderet som kombinationsterapi af glaukom sammen med timolol.
azopt was primarily evaluated in concomitant administration with timolol during adjunctive glaucoma therapy.

forholdet mellem område under koncentrationen ved kombinationsterapi og monoterapi var 4, 22.
the ratio of the auc on combination therapy to that on monotherapy was 4.22.

kombinationsterapi bør startes så tidligt som muligt, og fortsættes i mindst 4 uger efter
the benefit of the

antiretroviral kombinationsterapi kan forårsage ændringer i kropsfaconen på grund af ændringer i fordelingen af fedt.
combination antiretroviral therapy may cause changes in body shape due to changes in fat distribution.

hvis patienterne indberetter hypoglykæmi, bør tandemact dosen reduceres, eller fri kombinationsterapi bør overvejes.
if patients report hypoglycaemia, the dose of tandemact should be reduced or free combination therapy should be considered.

patienterne blev randomiseret til at få aza monoterapi, infliximab-monoterapi eller infliximab plus aza kombinationsterapi.
patients were randomised to receive aza monotherapy, infliximab monotherapy, or infliximab plus aza combination therapy.